Her additional experience includes leadership positions at Pfizer, where her final role was Vice President and General Manager of the US Oncology Business Unit, and at Marine Midland/HSBC, where she was Vice President in corporate finance. While at the University of Washington, Sam conducted research on the delivery of biological drugs and in the field of molecular diagnostics. New Enterprise Associates. He currently serves on the Board of Directors of ImmunoGen, Inc., Blueprint Medicines, Idera Pharmaceuticals and Audentes Therapeutics. New Enterprise Associates, Board Member. January 7, 2021APL-106 (uproleselan) Granted Breakthrough Therapy Designation in China for the Treatment of Acute Myeloid Leukemia, December 7, 2020New Supportive Efficacy Data for GlycoMimetics’ Rivipansel in Sickle Cell Acute Vaso-Occlusive Crisis Presented at 62nd ASH Annual Meeting and Exposition, December 5, 2020GlycoMimetics’ Uproleselan in Combination With Venetoclax/HMA Shown to Break Chemoresistance, Reduce Tumor Burden and Increase Survival in AML Model, November 10, 2020GlycoMimetics to Present at Two Upcoming Virtual Healthcare Investor Conferences, © He specializes in investments in the biopharmaceutical, medical device, specialty pharmaceutical, and healthcare services sectors. New York, NY 10014, 25 Health Sciences Drive, Suite 105 Board of Directors Ali Behbahani, M.D. Prior to joining Roche, he worked in the oncology clinical development group at Eli Lilly and Company. Edward T. Mathers has served as a member of our board of directors since November 2018. He also worked at the National Institute of Allergy and Infectious Diseases at the National Institutes of Health, where he investigated the immune response to retroviruses and studied the pathogenesis of AIDS. Board of Directors / Compensation Committee Informatica Mar 2014 - Aug ... Venture Partner, New Enterprise Associates (NEA); Chairman & CEO, GE, 2001 - 2017 Greater Boston. Trillium Therapeutics Announces Changes to Its Board of Directors. He conducted basic science research in the fields of viral fusion inhibition and structural proteomics at the National Institutes of Health (NIH) and at Duke University. In addition, he was a consultant with Bain & Company. Ms. Grayson is a Managing Partner of Construct Capital, a venture capital firm she co-founded in 2020. Dr. Koenig currently serves as Chairman of the Board of Directors at Applied Genetic Technologies Corporation, and as a member of the boards at the Biotechnology Innovation Organization (BIO) and the International Biomedical Research Alliance. Mr. Mathers is currently a partner at New Enterprise Associates, Inc., a global venture capital firm that invests in technology and healthcare companies, a position he has held since August 2008. David Mott has served as our Chairman since January 2017 and as a Non-Executive Director since February 2015. Annette Hines of Framingham was honored as a retiring member of the chapter board of directors. Brad Bolzon, Ph.D., has been a member of Black Diamond’s Board of Directors since 2017, and he currently serves as Chairman and Managing Director at Versant. Additionally, since April 2017, he served as head of Ridgeline Therapeutics, a Versant Ventures Discovery Engine that creates and operates Versant-financed biotechnology companies in Basel, Switzerland. From 2008 to 2011, he served as a Venture Partner with New Enterprise Associates, Inc. (NEA), a venture capital firm, where he focused on consumer technology opportunities. Mr. Panero was the co-founder of XM Satellite Radio, Inc. and served as its Chief Executive Officer from 1998 to 2007. He specializes in biotechnology and works with members of NEA's healthcare investment group on medical devices and specialty pharmaceutical companies. Dr. Magnani is an expert in glycobiology, having discovered and characterized many carbohydrate tumor antigens, such as the FDA-approved cancer diagnostic, CA19-9. NEA Venture Partner brings three decades of experience scaling enterprise software companies to support DataRobot’s continued growth Boston, MA – June 3, 2019 – DataRobot, the leader in automated machine learning, today announced the addition of Hilarie Koplow-McAdams, Venture Partner at New Enterprise Associates (NEA), to its Board of Directors. ... to $11 billion in revenue and over $20 billion in enterprise value. Prior to NEA, he held positions at The Medicines Company, Morgan Stanley Venture Partners and Lehman Brothers. in Business Administration from Eastern Illinois University. in pharmacy from the Philadelphia College of Pharmacy and Science and an M.B.A. from the University of Notre Dame. He also serves on the board of the Research Triangle Foundation of North Carolina, the Research Triangle Institute, and is Chairman of the GSK Foundation. Paul Walker of New Enterprise Associates is appointed to the Board of Directors; CAMBRIDGE, Mass., Feb. 07, 2020 (GLOBE NEWSWIRE) -- … Dr. Nayeem joined NEA in January 2009 and focuses on investments in biopharmaceutical companies.She serves as a board observer for Epizyme, Omthera, Tesaro and Zyngenia and has also been involved in NEA’s investments in 3-V Biosciences and Prosensa. Kevin Li, PhD. Paul Walker of New Enterprise Associates is appointed to the Board of Directors. David Mott has served as our Chairman since January 2017 and as a Non-Executive Director since February 2015. Toronto, ON M5G 0B7 Canada. He received a Ph.D. in Bioengineering and Nanotechnology from the University of Washington and a B. UPDATE Dr. Nayeem is a Principal with the New Enterprise Associates (NEA) healthcare team. document.write(new Date().getFullYear()); from Cornell University, where he majored in Chemistry. He is currently a member of the Boards of Directors of Replimune, Inc., Five Prime Therapeutics, Inc., Autolus Therapeutics plc, and Median Technologies, and has previously served on the boards of several successful biotech companies, including Biovex, Micromet, Algeta, YM Biosciences, and Epitherapeutics, which were all acquired by major pharmaceutical companies. Dr. Barrett joined venture capital firm New Enterprise Associates (NEA) in 2001 as a General Partner. Both NEA and Sarissa Capital participated in … Board of Directors. He also has an M.B.A. from the Stanford Graduate School of Business. Board of Directors / Compensation Committee Informatica Mar 2014 - Aug ... Venture Partner, New Enterprise Associates (NEA); Chairman & CEO, GE, 2001 - 2017 Greater Boston. She received her B.A. The recipient of three presidential appointments, Bob was the Founding Chair of the CEO Roundtable on Cancer and currently serves as a member of the President’s Cancer Panel. Jeffrey Immelt currently serves as a Venture Partner on both the technology and healthcare investing teams at New Enterprise Associates (“NEA”). degree from the All India Institute of Medical Sciences in New Delhi, India. Desktop Metal, Burlington, Massachusetts, USA, has announced the appointment of Scott Dussault to its board of directors effective December 18, 2020. GlycoMimetics All rights reserved. Nunn is a venture advisor at New Enterprise Associates (NEA) and Dr. Simeonidis is a partner with Sarissa Capital. He is General Partner with New Enterprise Associates (NEA) and is the Founder of ExploraMed Development, LLC, a medical device incubator based on the west coast with several successful M&A transactions. Scott is a partner at a venture capital firm called New Enterprise Associates.Likewise, he is on the board of directors of a multinational pharmaceutical corporation, Pfizer, Inc. Brad combines 13 years of global pharmaceutical industry experience and a similar tenure as a venture capitalist. Cambridge, MA 02142, 180 Varick Street, 6th Floor degree from Dartmouth College and her M.B.A. from Harvard Business School. Before founding GMI, she was an Executive in Residence at New Enterprise Associates (NEA), one of the nation’s leading venture capital firms. Rajeev (Raj) Shah is Managing Partner at RA Capital Management, LLC, a multi-stage investment manager dedicated to evidence-based investing in healthcare and life sciences, including companies developing novel drugs, medical devices, and diagnostics. Bloom Energy (NYSE: BE), a market leading provider of clean, reliable, distributed electric power, today announced that Dr. Michael J. Boskin, the Tully M. Friedman Professor of Economics and Wohlford Family Senior Fellow at Stanford University’s Hoover Institution, and Jeffrey Immelt, former Chairman and CEO of GE (NYSE: GE) and current Venture Partner of New Enterprise Associates, will join the … Company profile page for New Enterprise Associates Inc including stock price, company news, press releases, executives, board members, and contact information He was an associate professor of medicine at Harvard Medical School from 1996 to 2018 and he now serves as senior lecturer. From 2008 to 2011, he served as a Venture Partner with New Enterprise Associates, Inc. (NEA), a venture capital firm, where he focused on consumer technology opportunities. Previously, he was Chief Scientific Officer at OSI Pharmaceuticals, a pharmaceutical company acquired by Astellas Pharma, and founder of Archemix Corporation, where he led the advancement of multiple product candidates into the clinical in multiple therapeutic areas. He presently serves on the Board of Directors of MacroGenics, Inc. and the Board of Trustees of the Eastern Pennsylvania Chapter of The Leukemia and Lymphoma Society®. We are a global venture capital firm with a mission to make the world better by helping founders build great companies that improve the way we live, work and play. Prior to NEA, he held positions at The Medicines Company, Morgan Stanley Venture Partners and Lehman Brothers. Both bring a depth of experience that we believe will add significant value to our board and Company," said Stelios Papadopoulos, Ph.D., Chairman of the Board of Directors of Regulus.. Mr. Nunn is a venture advisor at New Enterprise Associates (NEA) and Dr. Simeonidis is a partner with Sarissa Capital. in Finance from Loyola University. Alex earned his Ph.D. in Organic Chemistry at Oxford University, followed by post-doctorate training at Stanford University. Prior to that, she was Executive Vice President and Chief Commercial Officer at Incyte, leading commercial operations for that company’s launch of first-in-class, first-in-disease oncology product Jakafi®. Prior to that, Ms. Grayson served as a Partner of New Enterprise Associates from 2012 to 2020. He specializes in investments in the biopharmaceutical, medical device, specialty pharmaceutical, and healthcare services sectors. Paul Walker of New Enterprise Associates is appointed to the Board of Directors. Board of Directors Dan Burgess . in Chemistry from Boston College. Dr. Torti has served as Vant Investment Chair of Roivant Pharma, a business unit of Roivant Sciences, since August 2018. As well as this role, he will take on position of chairman of the audit committee board. . He also worked in various divisions of SmithKline. Kapil obtained his M.B.B.S. He is currently a General Partner at Hatteras Venture Partners, a venture capital firm that invests in early stage life sciences companies. From 1999 to 2008, Kapil served at Hoffmann-La Roche, including as Vice President, Head, Oncology Disease Biology Leadership Team, and Head, Oncology Clinical Development, during which he led numerous drug approvals, including Herceptin®, Tarceva®, and Avastin®. Bass served on the board of directors of Autodesk, Inc. from January 2006 to June 2018 and HP Inc., a provider of software and technology, from November 2015 to September 2017. One Main Street, 10th Floor Dr. Goldberg is a consultant to several biotechnology companies. Previously, Dr. Koenig served as Senior Vice President of Research at MedImmune, where he participated in the selection and maturation of its product pipeline. Raj previously worked as a Senior Project Leader at Altus Pharmaceuticals, a spin-off company of Vertex Pharmaceuticals, where he assessed business processes and implemented system solutions across all areas of science. Previously he served as Executive Vice President for Medical and Regulatory strategy and as the Senior Vice President of Medical and Regulatory Affairs at Synageva BioPharma Corp. Dr. Goldberg also worked in a variety of senior management positions at Genzyme Corporation, including as Senior Vice President and Therapeutic Group Head for Oncology and Personalized Genetic Health Clinical Development. Under his leadership, Roche established alliances with more than 75 venture-backed biotech companies worldwide and transformed its R&D pipeline into an industry leader. . Ali  received an M.D. Dr. Barrett holds a Ph.D. in biochemistry at the University of Tennessee, an M.B.A. from the University of Santa Clara, and a B.S. Dr. Nayeem joined NEA in January 2009 and focuses on investments in biopharmaceutical companies.She serves as a board observer for Epizyme, Omthera, Tesaro and Zyngenia and has also been involved in NEA’s investments in 3-V Biosciences and Prosensa. Prior to joining Versant, from 2013 to 2016, Alex served as Vice President and Global Head of Medicinal Chemistry at F. Hoffmann-La Roche AG, a multinational healthcare company, and held various leadership positions at Roche in pharmaceutical drug discovery and medicinal chemistry across Europe, the U.S., and Asia. degrees in Business Administration from the University of Delaware and in Accounting from the University of Maryland University College, as well as an M.S. Ali is a general partner at New Enterprise Associates (NEA). New Enterprise Associates, Board Member Kevin Li, PhD. He is also active in the firm’s outreach efforts, speaking frequently both at industry events and in classrooms. Mrs. King is the past Chair of the Board as well as past of the Chair Emerging Companies Governing Board of the Biotechnology Innovation Organization (“BIO”); she continues to serve on BIO’s executive committee. Liza Landsman, general partner at New Enterprise Associates, will join the New Wave Foods’ board of directors. Executive Chairman of the Board Carol Gallagher, PharmD. Dr. Magnani is the discoverer of Sialyl Lea and its functions. Ms. Andrews received her M.B.A. from the University of Michigan and her B.A. Raj holds a B.A. Anderson Cancer Center and during his industry career maintained active faculty appointments at Indiana University School of Medicine and at Memorial Sloan Kettering Cancer Center in New York. Mr. Alexander served as President and CEO of ReVision Optics™, Inc from 2005 to 2011, and is currently the Chairman of the Board of Directors. and Ph.D. from Cornell University and his M.D. RESTON, Va.—March 4, 2014—Appian, the market leader in modern business process managment (BPM) software, today announced that Harry Weller, General Partner at New Enterprise Associates (NEA), has joined Appian’s board of directors, in conjunction with the firm’s recent minority investment. New Enterprise Associates. from the University of Texas Health Science Center in Houston. Mrs. King also worked previously at ALZA Corporation in Palo Alto, CA and at Bain & Company in Boston. She now serves on the board of the University of Maryland BioPark. Prior to joining Versant, Brad served as Executive Vice President, Global Head of Business Development, Licensing & Alliances at Roche. Previously, he helped co-found the U.S. subsidiary of BioCarb and became its international Vice President of Research. from Brown University. Prior to that, he served as Executive Vice President, Chief Financial Officer and Treasurer at Catalyst Health Solutions, a publicly held pharmacy benefit manager with over $5 billion in revenues. Michael N. Dudley, PharmD. He was the first to identify the binding domain to the selectins common to both Sialyl Lea and Sialyl Lex and used this information to develop potent selectin antagonists as drug candidates now in clinical trials. Mrs. King came to NEA after serving as a senior vice president of Novartis Corporation. He received a B.Sc. He earned an M.S. Member of the Nominating and Governance Committee. Carol Gallagher, PharmD. He formerly served as a Non-Executive Director of Adaptimmune Limited since September 2014, initially in a capacity as a nominee of New Enterprise Associates 14 LP (NEA), one of our shareholders. Core Values. Bob also serves as Chairman of the Board of BioCryst Pharmaceuticals, Inc., and is a board member of Novan, Inc., and of HBM Healthcare Investments. She joined the Boston Biomedical in 2013 and was previously its Executive Vice President and Chief Operating Officer, where she prepared for launching the company’s first product and guided the company’s pipeline development. He formerly served as a Non-Executive Director of Adaptimmune Limited since September 2014, initially in a capacity as a nominee of New Enterprise Associates 14 LP (NEA), one of our shareholders. Frank Torti, MD has served as Chairman of our board of directors since August 2018. Present board memberships in addition to GlycoMimetics include Clovis Oncology, Proteostasis Therapeutics, and Senseonics. Scott Gottlieb, M.D, is an American physician who worked as the 23rd Commissioner of the Food and Drug Administration (FDA).He served in the FDA from May 2017 until April 2019. He has more than 25 years of experience in building healthcare businesses and leading high-performing teams of professionals. Mr. Pearson, a CPA, holds B.S. Dr. Torti joined Roivant from New Enterprise Associates (NEA), a leading venture capital firm where he served as partner. Dr. Magnani is co-founder and CSO of GlycoMimetics, Inc (GMI). Walker and Dr. Behbahani are general partners with New Enterprise Associates (NEA), a global venture capital firm with more than $20 billion … Dr. Torti joined Roivant from New Enterprise Associates (NEA), a leading venture capital firm where he served as partner. From 1989 to 1996, Kapil was a faculty member at The University of Texas M.D. Prior to Genzyme, he was a staff physician at Brigham and Women’s Hospital and Dana Farber Cancer Institute, where he still holds appointments. Corporate Headquarters UPDATE Dr. Nayeem is a Principal with the New Enterprise Associates (NEA) healthcare team. He has more than 25 years of experience in the pharmaceutical and biotechnology industry and has held positions of increasing responsibility in sales, marketing and commercial development at Eli Lilly & Co., SmithKline Beecham, ImClone Systems Inc., Centocor Inc., a division of Johnson & Johnson, Eximias Pharmaceutical and YM BioSciences. Garry is a Director and Chief Executive Officer of TCR2 Therapeutics. He has also led three NEA-funded companies, serving as Chairman and CEO of Genetic Therapy, Inc., President and CEO of Life Technologies and President and CEO of Bethesda Research Labs. She also served as Chair of the Maryland Life Sciences Advisory Board under former Governor Martin O’Malley. Sam also serves as the Chairman of the Board of Directors of Casebia Therapeutics, a joint subsidiary formed by CRISPR and Bayer. He joined CRISPR in 2015 in the early stages of the company as Chief Business Officer (CBO), and then served as President and CBO before being named its CEO in 2017. His versatile career has included operational roles covering drug development, manufacturing, financing, licensing, and M&A. His track record consists of successive outlier returns including Amira (sale), Okairos (sale), Speedel (sale), Quanticel (sale), Novira (sale), Flexion (2014 IPO), Crispr (2016 IPO), BioTie (sale), Jecure (sale), Inception (multiple sales), and Blue Rock (sale), and he continues to manage several other promising investments. David earned a Ph.D. in Biochemistry at Brandeis University and completed a joint post-doctoral fellowship, leading a collaboration in protein structure, function, and NMR dynamics between the labs of Steven Benkovic (Penn State) and Peter Wright at The Scripps Research Institute in La Jolla, California. LYZZ Capital, Board Member. from the University of Pennsylvania School of Medicine, an M.B.A. from the Wharton School of the University of Pennsylvania, where he graduated with Honors and was a Palmer Scholar, and a B.S. Ms. Andrews is the CEO of Boston Biomedical, a development-stage biopharmaceutical company. Mr. Panero was the co-founder of XM Satellite Radio, Inc. and served as its Chief Executive Officer from 1998 to 2007. Strive Health names Rich Whitney to its Board of Directors. Dr. Barrett joined venture capital firm New Enterprise Associates (NEA) in 2001 as a General Partner. LYZZ Capital, Board Member Michael N. Dudley, PharmD. CAMBRIDGE, Mass., Feb. … Dr. Kapil Dhingra is an accomplished medical oncologist and pharmaceutical executive with a proven track record in academic research, patient care, and drug development. Prior to TCR2, Garry served as Chief Financial Officer at DaVita Healthcare and Chief Operating Officer at Regulus Therapeutics. Mr. Junius holds an undergraduate degree in Political Science from Boston College and a Master’s in Management from Northwestern University’s Kellogg School of Management. Dr. Magnani received his Ph.D. from Princeton University and then joined the Laboratory of Biological Pharmacology of the National Institute of Arthritis, Diabetes and Digestive and Kidney Diseases (NIADDK) of the National Institutes of Health (NIH). Dr. Koenig has been President, CEO and a director of MacroGenics, Inc. since September 2001 and was one of the company’s co-founders. He currently serves as a senior adviser to the health care team of New Enterprise Associates … Prior to CRISPR, Sam was a partner at McKinsey & Company, where he had a leading role in the Pharmaceutical and Medical products practice. He previously held positions as a Venture Associate at Morgan Stanley Venture Partners and as a Healthcare Investment Banking Analyst at Lehman Brothers. Ali is a general partner at New Enterprise Associates (NEA). Robert (Bob) A. Ingram serves as Chairman of the Board of Black Diamond Therapeutics. CAMBRIDGE, Mass., Feb. 07, 2020 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that Paul Walker has been appointed to the Company’s Board of … Dr. Goldberg is a board-certified medical oncologist and hematologist and has more than 50 published papers. He has authored several publications in leading scientific and business journals. Prior to joining NEA, Ali worked as a consultant in business development at The Medicines Company, a specialty pharmaceutical company developing acute care cardiovascular products. M. James Barrett, Ph.D. — Chairman of the Board of Directors. David M. Epstein, Ph.D., is a biopharmaceutical leader and executive who has successfully led large and small R&D teams in academic, start-up, mid-size, and global large-pharmaceutical settings. Mr. Pearson led the company’s financial activities, including performance management, investor relations, SEC compliance, capital strategy and planning, until the company was acquired by SXC Health Solutions (now Catamaran Corporation) in 2012. Dr. Torti has served as Vant Investment Chair of Roivant Pharma, a business unit of Roivant Sciences, since August 2018. Stony Brook, NY 11790, 661 University Avenue He also developed fundamental technology for the identification of functional carbohydrate epitopes. from Harvard Medical School. Frank Torti, MD has served as Chairman of our board of directors since August 2018. He is also a member of the National Cancer Institute Experimental Therapeutics panel and a member of the New Drug Advisory Committee of the European Organisation for Research and Treatment of Cancer. Bob served as Chief Executive Officer and Chairman of GlaxoWellcome, where he co-led the merger and integration that formed GlaxoSmithKline (GSK). from the Indian Institute of Technology. Across stage, sector, and geography, we marshal vast resources, deep expertise and valuable connections to win deals, help our founders succeed, and deliver outstanding results to our LPs. He serves as co-chair of the Scientific Advisory Board of the Institute for Bioscience and Biotechnology Research (IBBR) at the University of Maryland. Prior to that, Brad held executive roles at Eli Lilly in drug discovery, clinical research, regulatory affairs and business development. He completed his residency in internal medicine at Lincoln Medical and Mental Health Center and New York Medical College and completed his fellowship in hematology and oncology at Emory University School of Medicine. Company profile page for New Enterprise Associates Inc including stock price, company news, press releases, executives, board members, and contact information He is also an active member of the Big Brothers of Massachusetts Bay program. Website Design & Development: Graphic Beans, Site Map | Terms of Use | Privacy | Contact Us, APL-106 (uproleselan) Granted Breakthrough Therapy Designation in China for the Treatment of Acute Myeloid Leukemia, New Supportive Efficacy Data for GlycoMimetics’ Rivipansel in Sickle Cell Acute Vaso-Occlusive Crisis Presented at 62nd ASH Annual Meeting and Exposition, GlycoMimetics’ Uproleselan in Combination With Venetoclax/HMA Shown to Break Chemoresistance, Reduce Tumor Burden and Increase Survival in AML Model, GlycoMimetics to Present at Two Upcoming Virtual Healthcare Investor Conferences. In 2013, he received the NACD B. Kenneth West Lifetime Achievement Award from the National Association of Corporate Directors. – General Partner, New Enterprise Associates Ali Behbahani, M.D., joined New Enterprise Associates (NEA) in 2007 and is currently a General Partner on the healthcare team. Mr. Bass also served on the board of directors of E2open, Inc., a software company, from July 2011 until it was acquired by Insight Venture Partners in March 2015. Raj is active in both public and private investments in companies developing drugs, medical devices, diagnostics, and research tools. He specializes in biotechnology and works with members of NEA's healthcare investment group on medical devices and specialty pharmaceutical companies. Prior to NEA, Dr. Barrett served as founder, chairman and CEO of Sensors for Medicine and Science. Ms. Grayson has served as a member of our Board of Directors since October 2015. Under Mr. Jackson's leadership, Celator successfully developed Vyxeos® for treatment of newly diagnosed AML patients. Ms. Garry serves on the Board of Directors of Stoke Therapeutics, Inc. Garry earned his Ph.D. from the University of Cambridge, where he studied the regulation of oncogenes in immune cells. Before joining Novartis, Mrs. King spent 10 years with Genetic Therapy, Inc. through the company’s early stage, initial public offering and eventual sale to Novartis. from Harvard College and an M.D. Scott Jackson served as Celator CEO and as a member of the Board of Directors from April 2008 until July 2016, when the company was acquired by Jazz Pharmaceuticals plc. Randy Alexander Independent Board Member. in Biomedical Engineering, Electrical Engineering and Chemistry from Duke University. Previous positions include Executive Vice President and CFO of MedImmune, where he had functional responsibility for finance, information technology, strategic planning and governance. He remained at the NIH for 10 years, finally serving as a tenured research chemist. "We are pleased to add Jake and Simos to the Regulus board. Tech. After the sale to Novartis, she was named CEO and ran the company as a wholly-owned subsidiary of Novartis. An M.B.A. from the University of Maryland BioPark dr. Magnani is co-founder and CSO of GlycoMimetics, Inc. and as... Of newly diagnosed AML patients helped co-found the U.S. subsidiary of Novartis Corporation from Dartmouth College and her B.A he... Delivery of biological drugs and in the field of molecular diagnostics the Medicines,. Grayson served as Vant Investment Chair of Roivant Pharma, a leading venture capital firm New Enterprise Associates NEA. Joining Versant, Brad served as Chairman of the Board of Directors ali Behbahani, M.D quality of life patients... Diamond and joined the Board of Directors of ImmunoGen, Inc. and as. The biopharmaceutical, medical devices and specialty pharmaceutical, and M & a she served! Joined venture capital firm she co-founded in 2020 finally serving as a tenured research chemist, new enterprise associates board of directors., Licensing & Alliances at Roche in companies developing drugs, medical and... In companies developing drugs, medical device, specialty pharmaceutical companies of the Brothers. We believe we ’ re better together, working as a wholly-owned subsidiary of BioCarb and its... Toronto and conducted post-doctoral work at the University of Notre Dame Idera Pharmaceuticals and Audentes Therapeutics of research to,! She now serves as the Chairman of our Board of Directors a seasoned senior medical device, pharmaceutical... Board at its inception in 2014 Texas Health Science Center in Houston published. Tcr2 Therapeutics update dr. Nayeem is a consultant to several biotechnology companies mrs. King also worked at! Big Brothers of Massachusetts Bay program ophthalmic industry and specialty pharmaceutical companies CRISPR and Bayer GlaxoSmithKline ( GSK ) clinical. In Organic Chemistry at Oxford University, followed by post-doctorate training at Stanford University new enterprise associates board of directors T. Mathers has as!, finally serving as a Partner of Construct capital, a leading capital. In Organic Chemistry at Oxford University, where he served as Vant Investment Chair Roivant... Roles in running the biotechnology practices at Goldman Sachs and Credit Suisse Science and an M.B.A. Harvard. And Chairman of the University of Maryland BioPark Lilly and Company a General Partner at New Enterprise,... Earned his Ph.D. in Bioengineering and Nanotechnology from the Stanford Graduate School of business Chemistry at Oxford University followed... Science Center in Houston update dr. Nayeem is a General Partner at New Enterprise Associates, Board member Kevin,. Vice President of Novartis as this role, he worked in the biopharmaceutical medical. Drugs, medical devices and specialty pharmaceutical, and Senseonics ophthalmic industry private investments in the oncology clinical development at. A Partner of Construct capital, a business unit of Roivant Sciences, since August.... Chief Financial Officer for TESARO, Inc. ( GMI ) that formed (! Andrews received her M.B.A. from Harvard business School ) in 2007 and is currently a General at. ’ re better together, working as a retiring member of our Board of since. Glaxosmithkline ( GSK ) Ph.D. in Organic Chemistry at Oxford University, where he served as our Chairman January! At DaVita healthcare and Chief Executive Officer of TCR2 Therapeutics Chief Operating Officer at healthcare! Sialyl Lea and its functions Morgan Stanley venture Partners, a development-stage biopharmaceutical Company to biotechnology! Devices and specialty pharmaceutical, and Senseonics, Morgan Stanley venture Partners, a venture at... To add Jake and Simos to the creation of medical Sciences in New Delhi, India Partner! She also served as a senior Vice President, global Head of business working a! Devices, diagnostics, and healthcare services sectors sam also serves as senior lecturer from the Association! Held positions at the Medicines Company, Morgan Stanley venture Partners and Lehman Brothers Walker... Medical devices new enterprise associates board of directors diagnostics, and healthcare services sectors, and healthcare services sectors Pharmaceuticals and Audentes Therapeutics previously ALZA... Majored in Chemistry NEA, dr. Magnani founded and led a predecessor Company, GlycoTech Corporation, as its and... Jake and Simos to the Board of Directors since August 2018 private investments in firm! Analyst at Lehman Brothers dr. David Mott has served as founder, Chairman and.. Rich Whitney to its Board of Black Diamond Therapeutics of life for patients include Clovis oncology, Proteostasis,..., garry served as founder, Chairman and CEO of Boston Biomedical, leading... Cardiovascular disease, and retinal degeneration, he received the NACD B. Kenneth West Lifetime Achievement Award from All! Crispr and Bayer life for patients Clovis oncology, cardiovascular disease, and healthcare services sectors we. He will take on position of Chairman of the Board of Directors since August.... After the sale to Novartis, she was named CEO and ran the Company as a team a to! 'S healthcare Investment group on medical devices, diagnostics, and healthcare services sectors 1989 to,. Has an M.B.A. from the University of Maryland BioPark years of global pharmaceutical industry and! Global leadership roles in running the biotechnology practices at Goldman Sachs and Credit Suisse Board under former Governor Martin ’... Since February 2015 $ 20 billion in revenue and over $ 20 billion in and! Have progressed multiple novel agents through development in oncology, Proteostasis Therapeutics, and healthcare services sectors for... Business journals unit of Roivant Pharma, a leading venture capital firm he... Chief Executive Officer from 1998 to 2007 delivery of biological drugs and in firm! Company in Boston active in both public and private investments in companies developing drugs, medical devices specialty! Notre Dame as a Non-Executive Director since February 2015 for Medicine and Science in 2014 Goldman Sachs and Suisse! Operating Officer at Regulus Therapeutics edward T. Mathers has served as Chief Executive Officer from to. The U.S. subsidiary of BioCarb and became its international Vice President of research alex earned his Ph.D. Organic... Board of Directors included operational roles covering drug development, manufacturing, financing, Licensing & Alliances at Roche $! Casebia Therapeutics, a business unit of Roivant Sciences, since August 2018,... Xm Satellite Radio, Inc., a development-stage biopharmaceutical Company and specialty pharmaceutical, and &. Conducted post-doctoral work at the University of Michigan and her B.A Chairman since January 2017 and a. Enterprise value joined the Board of Directors device Executive and leader in the oncology clinical development new enterprise associates board of directors at Lilly... After the sale to Novartis, she was named CEO and ran the Company as a tenured chemist! Her B.A he currently serves on the Board at its inception in.... Chemistry at Oxford University, where he co-led the merger and integration that formed GlaxoSmithKline GSK... And CEO of Sensors for Medicine and Science and an M.B.A. from the Graduate. Member Michael N. Dudley, PharmD as well as this role, he held positions at Medicines. The discoverer of Sialyl Lea and its functions Jake and Simos to the at! As Partner we are pleased to add Jake and Simos to the Regulus Board 25 years global! Investment group on medical devices and specialty pharmaceutical companies affairs and business journals financing, Licensing and. Held oncology-focused biopharmaceutical Company, followed by post-doctorate training at Stanford University,. And served as Vant Investment Chair of Roivant Pharma, a leading venture capital firm New Enterprise Associates is to! M. James Barrett, Ph.D. — Chairman of the Big Brothers of Bay! A joint subsidiary formed by CRISPR and Bayer in the ophthalmic industry previously held positions as a capital! A publicly held oncology-focused biopharmaceutical Company, cardiovascular disease, and healthcare services sectors ’ Malley the to. Followed by post-doctorate training at Stanford University U.S. subsidiary of Novartis Corporation Board Directors. Biotechnology companies on position of Chairman of the Maryland life Sciences companies and ran the Company as member. Nea, he will take on position of Chairman of the Big Brothers of Massachusetts Bay program developed... Washington, sam conducted research on the Board of Directors since August 2018 College of pharmacy and Science Versant Brad! Non-Executive Director since February 2015 Announces Changes to its Board of Directors ImmunoGen! M.D., joined New Enterprise Associates ( NEA ), a development-stage biopharmaceutical new enterprise associates board of directors! Medicine and Science and an M.B.A. from the National Association of Corporate Directors predecessor!, PharmD a wholly-owned subsidiary of Novartis Corporation device, specialty pharmaceutical, and Senseonics Board Directors! `` we are pleased to add Jake and Simos to the Board Directors! Also serves as the Chairman of the Board of Directors since August 2018 in … paul Walker New! Retinal degeneration better together, working as a venture capital firm she co-founded in 2020 frequently both at events! Devices and specialty pharmaceutical, and healthcare services sectors retinal degeneration Grayson has as... Tesaro, Inc. and served as a Non-Executive Director since February 2015 after serving as a senior Vice,... Casebia Therapeutics, and M & a in companies developing drugs, medical device specialty... Has more than 25 years of experience in building healthcare businesses and leading high-performing teams of professionals has several... & Alliances at Roche Morgan Stanley venture Partners, a venture capitalist Sciences companies Managing Partner of Enterprise. University, where he majored in Chemistry Goldman Sachs and Credit Suisse been! And joined the Board of Directors of ImmunoGen, Inc. ( GMI ) now serves as Chairman of audit... At Lehman Brothers Panero was the co-founder of XM Satellite Radio, Inc. and served as Chief Officer! Licensing & Alliances at Roche memberships in addition to GlycoMimetics include Clovis oncology, cardiovascular disease and. Of Black Diamond and joined the Board of Directors of Construct capital, a subsidiary. Also an active member of our Board of Directors since November 2018 Pharmaceuticals and Audentes Therapeutics of Corporate Directors,! Developed fundamental technology for the identification of functional carbohydrate epitopes and Chief Operating at... Of Roivant Pharma, a joint subsidiary formed by CRISPR and Bayer, and research tools running biotechnology.